The primary objective for the Phase I portion of the study is to determine the maximum
tolerated dose (MTD) and dose limiting toxicities (DLTs) and for the Phase II portion of the
study is to evaluate progression free survival (PFS). Secondary objectives are response rate,
clinical benefit rate, and overall toxicity.